DK149886C - Analogifremgangsmaade til fremstilling af 5-methylisoxazol-4-carboxylsyre-(4-trifluormethyl)-anilid - Google Patents

Analogifremgangsmaade til fremstilling af 5-methylisoxazol-4-carboxylsyre-(4-trifluormethyl)-anilid

Info

Publication number
DK149886C
DK149886C DK534279A DK534279A DK149886C DK 149886 C DK149886 C DK 149886C DK 534279 A DK534279 A DK 534279A DK 534279 A DK534279 A DK 534279A DK 149886 C DK149886 C DK 149886C
Authority
DK
Denmark
Prior art keywords
methylisoxazole
anilide
analogy
trifluoromethyl
preparation
Prior art date
Application number
DK534279A
Other languages
English (en)
Other versions
DK534279A (da
DK149886B (da
Inventor
Friedrich-Johannes Kaemmerer
Rudolf Schleyerbach
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of DK534279A publication Critical patent/DK534279A/da
Publication of DK149886B publication Critical patent/DK149886B/da
Application granted granted Critical
Publication of DK149886C publication Critical patent/DK149886C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK534279A 1978-12-16 1979-12-14 Analogifremgangsmaade til fremstilling af 5-methylisoxazol-4-carboxylsyre-(4-trifluormethyl)-anilid DK149886C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2854439 1978-12-16
DE19782854439 DE2854439A1 (de) 1978-12-16 1978-12-16 Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung

Publications (3)

Publication Number Publication Date
DK534279A DK534279A (da) 1980-06-17
DK149886B DK149886B (da) 1986-10-20
DK149886C true DK149886C (da) 1987-04-21

Family

ID=6057414

Family Applications (1)

Application Number Title Priority Date Filing Date
DK534279A DK149886C (da) 1978-12-16 1979-12-14 Analogifremgangsmaade til fremstilling af 5-methylisoxazol-4-carboxylsyre-(4-trifluormethyl)-anilid

Country Status (25)

Country Link
US (2) US4284786A (da)
EP (1) EP0013376B1 (da)
JP (1) JPS5583767A (da)
AR (2) AR222680A1 (da)
AT (1) ATE1067T1 (da)
AU (1) AU529341B2 (da)
BG (1) BG60764B2 (da)
CA (1) CA1129867A (da)
DE (2) DE2854439A1 (da)
DK (1) DK149886C (da)
EG (1) EG13926A (da)
ES (2) ES486758A1 (da)
FI (1) FI64154C (da)
GR (1) GR72731B (da)
HU (1) HU178015B (da)
IE (1) IE49126B1 (da)
IL (1) IL58951A (da)
LU (1) LU90466I2 (da)
MX (2) MX6174E (da)
NL (1) NL990037I1 (da)
NO (1) NO148925C (da)
NZ (1) NZ192400A (da)
PH (1) PH16627A (da)
PT (1) PT70596A (da)
ZA (1) ZA796793B (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3247454A1 (de) * 1982-12-22 1984-06-28 Laboratorios Bago S.A., Buenos Aires Substituierte 3-phenyl-5-methyl-isoxazol-4-carboxy-anilide, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2538806B1 (fr) * 1982-12-30 1986-02-21 Bago Sa Labor Composes phenyl-3 methyl isoxazole-5 carboxy-4 anilides substitues, actifs therapeutiquement contre l'inflammation et la douleur
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
FR2662692B1 (fr) * 1990-05-30 1995-04-28 Novapharme Derives heterocycliques doues d'activite anticonvulsivante, procede de preparation et composition pharmaceutique.
US5258397A (en) * 1988-11-30 1993-11-02 Novapharme 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
DD297328A5 (de) 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
US5108999A (en) * 1990-02-02 1992-04-28 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
US5001124A (en) * 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
DE59010701D1 (de) * 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
US6133301A (en) * 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
DE59407412D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Interleukin 1 alpha
ATE174219T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
DE59407413D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
ATE174220T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von interleukin 8
TW314467B (da) * 1993-03-31 1997-09-01 Hoechst Ag
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
LT3589B (en) 1993-11-30 1995-12-27 Hoechst Ag Using of known combination for treatment of rejection reaction by transplantation of organs
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
ES2148561T3 (es) * 1994-10-17 2000-10-16 Aventis Pharma Ltd Prevencion y curacion de enfermedades alergicas de tipo i.
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
DE19702988A1 (de) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
DK0987256T3 (da) * 1997-08-08 2002-02-11 Aventis Pharma Gmbh Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
US20050255071A1 (en) * 1998-12-10 2005-11-17 Aventis Pharma Deutschland Gmbh Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
DE19960443C2 (de) * 1999-12-15 2002-05-08 Aventis Pharma Gmbh Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
HUP0301865A3 (en) * 2000-02-15 2005-12-28 Teva Pharma A method for synthesizing leflunomide
EP1473035A1 (en) * 2000-02-15 2004-11-03 Teva Pharmaceutical Industries Ltd. Leflunomide of high purity
US20020077485A1 (en) * 2000-08-14 2002-06-20 Ilya Avrutov Micronized leflunomide
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
DK1381356T3 (da) 2001-04-05 2008-09-22 Aventis Pharma Inc Anvendelse af (z)-z-cyano-3-hydroxy-but-2-enoinsyre-(4-trifluoromethylphenyl) - amide til behandling af multipel sclerose
US20030139606A1 (en) * 2001-11-09 2003-07-24 Ray Anup Kumar Process for preparing 5-methylisoxazole-4-carboxylic- (4'-trifluoromethyl)-anilide
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
KR20080038339A (ko) * 2005-08-31 2008-05-06 코와 가부시키가이샤 관절 류머티즘의 예방 및/또는 치료법
WO2008093246A2 (en) 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
CN101817797B (zh) * 2009-02-26 2013-04-10 江苏亚邦爱普森药业有限公司 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US10889548B2 (en) 2018-03-26 2021-01-12 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
MX2022010962A (es) 2020-03-06 2022-10-07 Actelion Pharmaceuticals Ltd Metodos para ralentizar la perdida de volumen cerebral.
US11951097B2 (en) 2021-10-11 2024-04-09 Vanda Pharmaceuticals Inc. Methods of treating multiple sclerosis
WO2023152290A1 (en) 2022-02-11 2023-08-17 Actelion Pharmaceuticals Ltd Methods of slowing an increase in brain ventricular volume

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087534A (en) * 1974-05-22 1978-05-02 David Ovadia N-haloalkylmio urazole pesticides
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
DE2654797A1 (de) * 1976-12-03 1978-06-08 Hoechst Ag Verfahren zur herstellung von isoxazolderivaten

Also Published As

Publication number Publication date
BG60764B2 (bg) 1996-02-29
IE792426L (en) 1980-06-16
IL58951A0 (en) 1980-03-31
ES486750A1 (es) 1980-06-16
MX6174E (es) 1984-12-04
LU90466I2 (fr) 2000-01-03
ZA796793B (en) 1980-11-26
JPH0133470B2 (da) 1989-07-13
NO148925B (no) 1983-10-03
IE49126B1 (en) 1985-08-07
US4351841A (en) 1982-09-28
PT70596A (de) 1980-01-01
PH16627A (en) 1983-12-05
FI793899A (fi) 1980-06-17
DK534279A (da) 1980-06-17
ES486758A1 (es) 1980-05-16
EP0013376A2 (de) 1980-07-23
NL990037I2 (nl) 2000-01-03
DE2854439A1 (de) 1980-07-03
JPS5583767A (en) 1980-06-24
CA1129867A (en) 1982-08-17
EG13926A (en) 1982-09-30
NL990037I1 (nl) 2000-01-03
NO148925C (no) 1984-01-11
FI64154C (fi) 1983-10-10
AU5385379A (en) 1980-06-19
AR226894A1 (es) 1982-08-31
AU529341B2 (en) 1983-06-02
FI64154B (fi) 1983-06-30
DE2962929D1 (en) 1982-07-08
ATE1067T1 (de) 1982-06-15
IL58951A (en) 1984-01-31
NO794094L (no) 1980-06-17
HU178015B (en) 1982-02-28
EP0013376B1 (de) 1982-05-19
MX8403A (es) 1994-03-31
NZ192400A (en) 1982-02-23
GR72731B (da) 1983-12-01
DK149886B (da) 1986-10-20
AR222680A1 (es) 1981-06-15
EP0013376A3 (en) 1980-09-17
US4284786A (en) 1981-08-18

Similar Documents

Publication Publication Date Title
DK149886C (da) Analogifremgangsmaade til fremstilling af 5-methylisoxazol-4-carboxylsyre-(4-trifluormethyl)-anilid
DK428179A (da) Fremgangsmaade til fremstilling af metaboliter
DK156253C (da) Fremgangsmaade til fremstilling af pyruvatoxidase
DK520679A (da) Fremgangsmaade til fremstilling af 3-quinolincarboxulsyrederivater
DK366778A (da) Fremgangsmaade til taelling af bakterier
DK359182A (da) Fremgangsmaade til fremstilling af d-maelkesyre
DK277880A (da) Fremgangsmaade til fremstilling af dipeptider
DK459579A (da) Fremgangsmaade til fremstilling af 1,2,3-thiadiazol-5-ylurinstoffer
DK229479A (da) Fremgangsmaade til fremstilling af forbindelser af muramylpeptidtypen
DK87079A (da) Fremgangsmaade til fremstilling af dialkylphospohorchloridothioter
DK152752C (da) Fremgangsmaade til fremstilling af l-sulpirid
DK224079A (da) Fremgangsmaade til fremstilling af nitroforbindelser
DK226579A (da) Fremgangsmaade til fremstilling af metaboliter
DK532478A (da) Fremgangsmaade til fremstilling af cement
DK231481A (da) Fremgangsmaade til fremstilling af diacetonektetogulonsyre
DK431083D0 (da) Fremgangsmade til fremstilling af hydroxylaminderivater
DK36379A (da) Fremgangsmaade til fremstilling af n-ethylethylendiamin
DK143107C (da) Fremgangsmaade til fremstilling af 2-isopropylaminopyrimidin
DK187579A (da) Fremgangsmaade til fremstilling af alfa-(4-(4-chlorbenzoylamino-ethyl)-phenoxyl)-isosmoersyre
DK147420C (da) Fremgangsmaade til fremstilling af acylcyanider
DK274480A (da) Fremgangsmaade til fremstilling af pyrenzepin
DK79079A (da) Fremgangsmaade til fremstilling af vaegbeklaedning
DK19779A (da) Fremgangsmaade til fremstilling af aminomalosyredinitril
DK195979A (da) Fremgangsmaade til fremstilling af d-homosteroider
DK149185C (da) Analogifremgangsmaade til fremstilling af trialkylsilylpropionsyreamider